Table 1.
Demographic and clinical features of choroidal melanoma (CM) patients (n = 18).
| Age (Mean ± SD) | 61.2 ± 18.9 |
| Gender (n) | |
| Male | 9 |
| Female | 9 |
| Quadrant location (n) | |
| Temporal | 3 |
| Nasal | 4 |
| Inferior | 4 |
| Superior | 4 |
| Posterior pole | 3 |
| Antero-posterior location (n) | |
| Anterior to the equator | 6 |
| Posterior to the equator | 8 |
| Posterior pole | 3 |
| Posterior pole to CB | 1 |
| Ciliary body (CB) involvement 1 (n) | |
| Yes | 5 |
| No | 13 |
| Largest basal diameter (LBD) 2 (n) | |
| <12 mm | 2 |
| ≥12 mm | 16 |
| Tumor thickness 3 (n) | |
| <7 mm | 12 |
| ≥7 mm | 6 |
| Subretinal fluid (n) | |
| Yes | 15 |
| No | 3 |
| Drusen (n) | |
| Yes | 5 |
| No | 13 |
| Treatment (n) | |
| Plaque radiotherapy | 12 |
| Enucleation | 6 |
| Gene expression profiling class 4 (n) | |
| Class 1 | 11 |
| Class 2 | 7 |
1 CB involvement was determined by clinical examination and ocular transillumination and confirmed by B-scan ultrasonography and ultrasound biomicroscopy. 2 LBD was estimated by indirect ophthalmoscopy with fundus mapping and ocular transillumination (when possible). Mean LBD was 15 mm (median 14.5 mm, range 9 to 24 mm). 3 Tumor thickness was measured using B-scan ultrasonography by placing the markers between the top of the tumor just under the retina and the base of the tumor just above the sclera. Mean tumor thickness was 5.9 mm (median 5.2 mm, range 1 to 10.8 mm). 4 Gene expression profiling of the primary tumor was performed using a clinically validated and commercially available 15-gene assay (DecisionDx-UM®) [28] to predict the metastatic risk: Class 1—low risk and Class 2—high risk.